Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
News|Videos|May 20, 2024
ETHOS Post-Hoc Analysis: Dave Singh, MD, Highlights Breztri Reduction of Cardiopulmonary Risk in COPD
Author(s)Grace Halsey
The triple therapy cut risk of a first cardiopulmonary event by 20% vs dual therapy in addition to significantly reducing COPD exacerbations, PI Singh told Patient Care.
Advertisement
Triple inhaled therapy with budesonide/glycopyrrolate/formoterol fumarate was more effective than 2 dual therapy formulations for reduction of the risk of a first cardiopulmonary event in persons with moderate to very severe chronic obstructive pulmonary disease, according to findings of a pivotal post-hoc analysis of the ETHOS phase 3 clinical trial presented at the American Thoracic Society 2024 International Conference. Principal investigator Dave Singh, MD, professor of respiratory pharmacology at the University of Manchester in Manchester, England, highlights the original study, rationale for the post-hoc analysis, and the encouraging findings in an interview with Patient Care® in the short video above.
Singh presented findings on behalf of the COURSE study group from Effect of triple inhaled therapy with budesonide/glycopyrrolate/formoterol fumarate on cardiopulmonary events in chronic cardiopulmonary events in chronic obstructive pulmonary disease: a post-hoc analysis of ETHOS at the 2024 American Thoracic Society International Conference, May 17-22, 2024, in San Diego, CA.
Advertisement
Related to this article
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.
Advertisement
Advertisement